Escugen
Latest round
- Series A
Last raised
- May 2023
Total raised
- $14M
Investors
- 3
About Escugen
Established in 2017 based in Shanghai, China, is a biopharmaceutical company that develops antibody drugs for malignancies and other areas. The company develops drugs mainly by target innovation and specific combination therapy to expand differentiated clinical pathways, and has an entrepreneurial team covering the entire professional chain of biologics R&D. The company is mainly developing new drugs for innovative ADCs and currently has three pipeline products in clinical trials. The pioneer pipeline ESG401 is an ADC targeting TROP-2, which has efficacy in triple negative breast cancer and HR positive breast cancer. Another clinical-stage pipeline, ESG206, targets relapse-resistant and refractory lymphomas and leukemias and can be further expanded to multiple autoimmune diseases. ESG103 single-domain antibody will be combined with our partner's proprietary new drug to treat major oncology indications not covered by similar drugs.
Who invested in Escugen
3 investors across 1 round
See all investors in Escugen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 31, 2023
Amount
$14M
Investors
Questions about Escugen
Who invested in Escugen?
Escugen has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Escugen raised?
Escugen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Escugen last raise money?
Escugen's most recent round on record is a Series A, in May 2023.
What does Escugen do?
Established in 2017 based in Shanghai, China, is a biopharmaceutical company that develops antibody drugs for malignancies and other areas.
Where is Escugen headquartered?
Escugen is headquartered in Shanghai, China.
Which VCs invest in companies like Escugen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Escugen's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Escugen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.